Fed-batch methods for producing adalimumab

Patent metadata

Field	Value
Publication number	US-9234032-B2
Application number	US-201414157460-A
Country	US
Kind code	B2
Filing date	Jan 16, 2014
Priority date	Sep 13, 2006
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture.

First claim

What is claimed:

1. A fed-batch method for producing adalimumab in mammalian cells in culture, wherein said mammalian cells express said adalimumab, the method comprising:
culturing the mammalian cells in a cell culture production medium in large scale at a first temperature; and
then reducing the temperature under which the mammalian cells are cultured to a second lower temperature during adalimumab production, wherein said adalimumab is produced at a titer of at least 1.3 g/L in said cell culture and said adalimumab is further purified by a process including Protein A affinity chromatography.

2. The fed-batch method according to claim 1 , wherein the first temperature is 35° C., 37° C., or 38° C.

3. The fed-batch method according to claim 1 , wherein the second temperature is 32° C. or 33° C.

4. The fed-batch method according to claim 1 , wherein the first temperature is 37° C. and the second temperature is 33° C.

5. The fed-batch method according to claim 1 , wherein the first temperature is 37° C. and the second temperature is 32° C.

6. The fed-batch method according to claim 1 , wherein the first temperature is 35° C. and the second temperature is 32° C.

7. The fed-batch method according to claim 1 , wherein the cell culture production medium comprises at least two different non-animal-based hydrolysates.

8. The fed-batch method according to claim 7 , wherein the non-animal-based hydrolysates comprise a plant-based hydrolysate and a yeast-based hydrolysate.

9. The fed-batch method according to claim 8 , wherein the plant-based hydrolysate is a soy-based hydrolysate.

10. The fed-batch method according to claim 1 , wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells and the cell culture production medium is supplemented with a 25× PFCHO solution and a 33× solution of a combination of the plant-based hydrolysate Phytone and yeast-based hydrolysate Yeastolate.

11. The fed-batch method according to claim 1 , wherein the cell culture production medium maintains a glucose concentration of at least 2 g/L.

12. The fed-batch method according to claim 1 , wherein the cell culture production medium comprises:
a) a modified basal medium;
b) 8 to 10 ml/kg or 110 to 130 mg/L ferric citrate;
c) 4 to 8 mL/kg or 10 to 14 mg/kg recombinant human insulin;
d) 5 to 9 g/kg anhydrous glucose;
e) 0.1 to 1 g/kg L-glutamine;
f) 1 to 3 g/kg sodium bicarbonate;
g) 1 to 3 g/kg HEPES;
h) 2 to 3 g/kg NaCl;
i) 0.1 to 2 g/kg Pluronic F-68;
j) 0.01 to 0.1 g/kg NaH 2 PO 4 —H 2 O;
k) 0.1 to 0.1 g/kg Na 2 HPO 4 -7H 2 O;
l) 8 to 12 g/kg yeast-based hydrolysate; and
m) 6 to 8 g/kg plant-based hydrolysate.

13. The fed-batch method according to claim 1 , wherein said adalimumab is produced at a titer of at least 2 g/L in said cell culture.

14. The fed-batch method according to claim 13 , wherein said adalimumab is produced at a titer of at least 4 g/L in said cell culture.

15. The fed-batch method according to claim 1 , wherein the temperature is reduced after at least 3 days of culturing the mammalian cells at the first temperature.

16. The fed-batch method according to claim 1 , further comprising culturing the mammalian cells in the cell culture production medium in large scale at a starting pH; and then reducing the pH during adalimumab production phase to a value that is less than the starting pH.

17. The fed-batch method according to claim 16 , wherein the starting pH is 8 or less and the reduced pH is 6.5 to 7.0.

18. The fed-batch method according to claim 17 , wherein the starting pH is 7.1 and the reduced pH is 6.9.

19. The fed-batch method according to claim 18 , wherein the pH is adjusted within the first 72 hours of culturing.

20. The fed-batch method according to claim 17 , wherein the first temperature is 35° C., 37° C., or 38° C., and the second temperature is 32° C. or 33° C.

21. The fed-batch method according to claim 20 , wherein the mammalian cells expressing adalimumab are cultured at a viable cell density of between 2.0×10 6 cells/mL and 5.0×10 6 cells/mL.

22. The fed-batch method according to claim 20 , wherein the mammalian cells expressing adalimumab are cultured at a viable cell density of between 3.5×10 6 cells/mL and 5.0×10 6 cells/mL.

23. The fed-batch method according to claim 17 , further comprising (1) monitoring the glucose concentration in the cell culture production medium and (2) maintaining the glucose concentration in the cell culture production medium at a concentration of at least 2 g/L, or adding glucose to the cell culture production medium when the glucose concentration in the cell culture production medium decreases to below 2 g/L.

24. The fed-batch method according to claim 17 , further comprising (1) monitoring the glucose concentration in the cell culture production medium and (2) maintaining the glucose concentration in the cell culture production medium at a concentration of at least 2 g/L but no greater than 7 g/L.

25. The fed-batch method according to claim 17 , further comprising (1) monitoring the glucose concentration in the cell culture production medium and (2) maintaining the glucose concentration in the cell culture production medium at a concentration of at least 2 g/L but no greater than 5 g/L.

26. The method according to claim 24 , wherein the osmolarity of the cell culture production medium is 440 mOsm or less, and wherein the first temperature is 35° C., 37° C., or 38° C., and the second temperature is 32° C. or 33° C.

27. The method according to claim 26 , wherein the cell culture production medium is maintained at between 20-65% dissolved oxygen.

28. The method according to claim 26 , wherein the cell culture production medium is maintained at about 30% dissolved oxygen.

29. The method according to claim 26 , wherein the large-scale cell culture is greater than about 10 L.

30. The method according to claim 26 , wherein the large-scale cell culture is 13 L.

31. The method according to claim 26 , wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.

Assignees

• Abbvie Inc

Inventors

• Pla Itzcoatl A
• Matuck Joseph G
• Fann John C
• Schulz Christof
• Roy Nichole A
• Bruton David F
• Mcintire James
• Chang Yu-Hsiang D
• Seewoester Thomas

Classifications

• C12N2500/24

  Iron; Fe chelators; Transferrin · CPC title

• C12N2501/33

  Insulin · CPC title

• C12N2500/50

  Soluble polymers, e.g. polyethyleneglycol [PEG] · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title

• C12N2500/90

  Serum-free medium, which may still contain naturally-sourced components · CPC title